You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Elvucitabine
(ACH-126,443, or Beta-L-Fd4C)

Also known as ACH-126443, L-Fd4C or beta-L-Fd4C, elvucitabine is a NRTI currently under investigation for the treatment of HIV infection and chronic hepatitis B.

In addition to its anti-HIV effects, elvucitabine has potent anti-HBV activity in laboratory studies. A Phase I/II study of elvucitabine in patients with chronic HBV infection demonstrated acceptable pharmacokinetics and safety. Phase II studies of elvucitabine in HBV-infected patients are underway.


Newer Anti-HIV Drugs and How to Use Them: Part I
6/23/09


Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks

11/07/08


 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children